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Abstract: 
A crucial virulence factor for intracellular Mycobacterium tuberculosis survival is Protein kinase G (PknG), a eukaryotic-like serine-
threonine protein kinase expressed by pathogenic mycobacteria that blocks the intracellular degradation of mycobacteria in 
lysosomes. Inhibition of PknG results in mycobacterial transfer to lysosomes. Withania somnifera, a reputed herb in ayurvedic 
medicine, comprises a large number of steroidal lactones known as withanolides which show various pharmacological activities. 
We describe the docking of 26 withanferin and 14 withanolides from Withania somnifera into the three dimensional structure of 
PknG of M. tuberculosis using GLIDE. The inhibitor binding positions and affinity were evaluated using scoring functions-
Glidescore. The withanolide E, F and D and Withaferin - diacetate 2 phenoxy ethyl carbonate were identified as potential inhibitors 
of PknG. The available drug molecules and the ligand AX20017 showed hydrogen bond interaction with the aminoacid residues 
Glu233 and Val235. In addition to Val235 the other amino acids, Gly237, Gln238 and Ser239 are important for withanolide inhibitor 
recognition via hydrogen bonding mechanisms. 
 
 
 
 
Background:  
Mycobacterium tuberculosis continues to kill millions of people 
yearly worldwide and tuberculosis continues to be a major 
health problem.  Despite the existence of effective 
chemotherapies, no new drugs have come to the market in >40 
years.  In addition the rise in drug resistance among M. 
tuberculosis strains is becoming a severe threat to public health, 
illustrated by the recent emergence of extensively drug-resistant 
tuberculosis (XDR-TB) that has caused a mortality of >98% [1]. 
Virulence of pathogenic mycobacteria is related to their capacity 
to survive for prolonged times within macrophage phagosomes 
[2, 3], whereas, normally internalized and phagocytosed 
bacteria are rapidly degraded within phagolysosomes, and 
pathogenic mycobacteria have evolved to block lysosomal 
delivery  [3].  One strategy by which pathogenic mycobacteria 
prevent lysosomal maturation is through the activity of 
mycobacterial protein kinase G (PknG), a eukaryotic-like 
serine/threonine protein kinase that is not required for 
mycobacterial growth per se but is essential for survival within 
host macrophages [4, 5]. This PknG blocks the intracellular 
degradation of mycobacteria in lysosomes [6]. It is involved in 
host cell signal transduction capable of modulating host 
macrophage trafficking pathways [7]. Importantly, 
mycobacteria overexpressing a kinase-dead mutant of PknG are 
rapidly transferred to lysosomes and killed, demonstrating that 
PknG kinase activity is crucial for mycobacterial survival [8]. 
The fact that PknG is translocated into the host cytosol suggests 
that compounds aimed at blocking PknG activity do not require 
transport across the only limited permeable mycobacterial cell 
wall [4]. Together, these findings make PknG an attractive and 
promising drug target. Indeed, blocking PknG kinase activity 
by a specific inhibitor results in rapid transfer of mycobactera to 
lysosomes and killing of the intracellularly residing bacilli. 
PknG is a multidomain protein (Figure 1) consisting of a 
rubredoxin, kinase and tetratricopeptide repeat domain and 
show that the rubredoxin domain is essential for the activity of BIOINFORMATION  open access 
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PknG. The structure reveals that the inhibitor-binding pocket is 
shaped by a unique set of amino acid residues that, in 
combination, is not found in any human kinase [8, 9]. This 
structural information provides the basis for the identification 
of novel compounds aimed at blocking the proliferation of M 
tuberculosis from W. somnifera. 
 
Plants are rich in a wide variety of secondary metabolites such 
as tannins, terpenoids, alkaloids, flavonoids etc. which have 
been found to have antimicrobial properties. Withania somnifera 
(L) Dunal (Aswaghanda or Indian “Ginseng”) is widely used in 
ayurvedic medicines and is consumed as a dietary supplement 
around the world [10]. The major bioactive compounds of 
Ashwagandha are steroidal lactones compounds known as 
withanolides. They also contain several alkaloids, withanosides, 
reducing sugars, few flavonoids, tannins etc. [10]. These 
compounds have shown to possess a remarkable range of 
therapeutic properties. Other investigations indicated that leaf 
extracts of W. somnifera also has antibacterial properties [11]. 
The withanolides are C28-steroidal lactones built on an intact or 
rearranged ergostane framework, in which C-22 and C-26 are 
approximately oxidized to form a six-membered lactone ring. 
The basic structure (Figure 2) is designated as the withanolide 
skeleton. There are many novel structural variants of 
withanolides with modifications either of the carbocyclic 
skeleton or the side chain and these have often been described 
as modified withanolides or ergostan-type steroids related to 
withanolides. Hence, the present study was aimed to identify 
the potential PknG inhibitors from W. somnifera by molecular 
docking studies using Glide (Schrӧdinger). 
 
 
Figure 1: Structure of the PknG-AX20017 complex (PDB ID 
2PZI). 
 
Methodology: 
Selection of docking molecules: 
A set of 26 withaferin and 14 withanolide derivatives were 
downloaded from pubchem database 
[http://pubchem.ncbi.nlm.nih.gov/] for the docking studies. 
Similarly the commercially available drugs namely Ciproflaxin, 
Kanamycin,  Isoniazid, Ethionamide, Prothionamide, 
Pyrazinamide, Amino salicylic acid, Cycloserine, Streptomycin 
and Ethambutol were taken from the literature. All the ligands 
were built using Maestro build panel.  The collected ligands 
were prepared by using LigPrep [Schrodinger] which uses 
MMFF 94s force field and gave the corresponding low energy 
3D conformers of the ligands. These ligands were neutralized 
and checked for their ADME properties using QikProp 
(Schrodinger).  QikProp helps in analyzing the 
pharmacokinetics and pharmacodynamics of the ligand by 
assessing the drug like properties.  
 
 
Figure 2: (A) Basic structure of Withanolides, (B) Basic structure 
of Withaferin A 
 
Target propein preparation: 
The three dimensional crystal structure of PknG from M. 
tuberculosis in Complex with Tetrahydrobenzothiophene 
AX20017 (PDB Id: 2PZI) was downloaded from the Protein Data 
Bank (PDB) (http://www.rcsb.org) (Figure 1). Before docking 
the ligands into the protein active site, the protein was prepared 
using protein preparation wizard of Schrodinger’s molecular 
docking software.  In this protein preparation all water 
molecules and hetero atoms were removed. Hydrogen atoms 
were added to the protein, including the necessary to define the 
correct ionization and tautomeric states of amino acid residues 
such as Asp, Ser, Glu, Arg and His. The active site of the protein 
was defined for generating the grid. The screened ligands were 
then docked into the prepared grid, for which “standard 
precision mode” was selected. No constraints were defined. 
 
Docking: 
Docking was carried out using GLIDE (Grid-Based Ligand 
Docking with Energies) software. Glide searches for favourable 
interaction between one or more ligand molecules and a 
receptor molecule. The combination of position and orientation 
of a ligand relative to receptor, along with its conformation in 
flexible docking, is referred to as a ligand pose.  The ligand 
poses that Glide generates, pass through a series of hierarchical 
filters that evaluate the ligands interaction with the receptor. 
The initial filters test the spatial fit of the ligand to the defined 
active site, and examine the complementarity of ligand-receptor 
interactions using a grid-based method patterned after the 
empirical ChemScore function. Poses that pass these initial 
screens enter the final stage of the algorithm, which involves 
evaluation and minimization of a grid approximation to the 
OPLS-AA nonbonded ligand-receptor interaction energy. Final 
scoring is then carried out on the energy-minimized poses. 
GlideScore is based on the ChemScore, but includes a steric-
clash term and adds buried polar atoms devised by Schrodinger 
to penalize electrostatic mismatches: Gscore=0.065*vdW + 
0.130*Coul + Lipo + Hbond + BuryP + RotB + Site. 
 
Results and Discussion: 
Out of 40 withanolide derivative compounds, only 10 
compounds showed better interaction with the target protein. 
The docking confirmation with best GlideScore had been 
analyzed. 
 BIOINFORMATION  open access 
 
ISSN 0973-2063 (online) 0973-8894 (print)     
Bioinformation 7(1): 1 - 4 (2011)  3   © 2011 Biomedical Informatics
 
Binding mode of available antituberculosis drug molecules: 
The GlideScore values of available drug molecules range 
between -4.40 and -6.91 (Table 1, see Supplementary material). 
The drug Kanamycin and Isoniazid showed the better 
interaction than the other drug molecules and the GlideScore 
values are -6.91 and -6.63. The main chain amino acids Glu233 
and Val235 form hydrogen bonds, with the drug molecules.  
 
Binding mode of compound AX20017: 
The compound AX20017 inhibitor is bound deep within a 
narrow pocket formed by the inter lobe cleft of the kinase 
domain as reported in the x-ray crystallographic structure [9] 
and the G-Score value is -5.6 (Table 2, see Supplementary 
material). The main chain Glu233:O and Val235:NH of PknG 
form hydrogen bonds with inhibitor (Figure 3).  
 
 
Figure 3: Potential docking pose for the ligands (A) withanolide 
D, (B) withanolide E and (C) withanolide F within the active 
site of PknG 
 
Binding mode of bioactive compounds from W. somnifera: 
The binding efficiency of the bioactive compounds from W. 
somnifera is shown in Table 2 (see Supplementary material) 
and the G-score value is ranging between -4.58 to -7.86. Out of 
22 compounds tested, Withanolide E, F and D showed the best 
G-Score value of -7.86, – 7.69, and -7.63 respectively than the 
withaferin and currently existing drug molecules.  More 
negative GlideScore value indicates the better interaction of the 
inhibitor with the target protein. A comparison of the different 
docking poses of compounds suggests that the compounds 
namely withanolide E, F and D showed fairly potent activity 
against PknG with the more negative G-Score value than the 
available drug molecules The bioactive compounds was 
positioned in a similar orientation like Ax20017 and forming 
hydrogen bonding with the residues Glu233, Val235, Gly237, 
Gln238, Ser239, Lys241, Ile292 and Ser293 of the kinase domain 
as shown in Table 2 (see Supplementary material).  The 
calculated distances between these residues and the ligand 
molecule ranged from 2.671 to 3.429 Å. The presence of strong 
hydrogen bond interactions between the oxygen atom of the 
ligands and Val235 was observed.  This hydrogen-bonding 
network places the inhibitor such that van der Waals contacts 
are made with the side chains of Ala158, Ile165, Val179, Lys181, 
Met232, Ile292 and Asp293 of PknG. These results indicate that 
the predicted nonbonding interactions and hydrophobic chains 
to accommodate the ligands are similar to the experimental data 
obtained from crystal structure as reported in the earlier studies 
[8]. The ADME properties indicated that withanolides obey the 
Lipinski’s rule of five (Table 3, see Supplementary material) 
the basic rules to be followed by a candidate drug molecule. 
 
Conclusion:  
Withanolide D, E and F show better with PknG  based on 
GlideScore and interaction with the active site residues in 
comparison with the existing drug molecules.  This data 
provides molecular insights to the consideration of 
Withanolides as potential candidates against the PknG target in 
M. tuberculosis. 
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Supplementary material: 
 
Table 1: XP Docking of available drug molecules with PknG of M. tuberculosis  
S. No  Compounds  Glide Score  Glide Energy  H Bond Interaction  Bond Distance(DH…A) 
Å 
1 Ciproflaxin  -4.40  -31.959  (NH…O)A:GLU  233  2.853 
2 Kanamycin  -6.91  -48.195  (OH…O)A:SER  239 
 (NH…O)A:VAL 235 
3.252 
3.125 
3 Isoniazid  -6.63  -28.956  (NH…O)A:ILE 292 
 (NH…O)A:VAL 235 
2.459 
2.965 
4 Ethionamide  -5.31  -26.184  (NH…O)A:GLU 233  2.698 
5 Prothionamide  -5.82  -29.590  (NH…O)A:GLU 233  3.124 
6 Pyrazinamide  -4.54  -27.236  (NH…O)A:GLU 233 
 (NH…O)A:VAL 235 
2.568 
2.867 
7 Amino  salicylic  acid  -5.19  -24.377  (NH…O)A:GLU 233 
 (NH…O)A:VAL 235 
3.214 
3.312 
8 Cycloserine  -4.34  -21.498  (NH…O)A:VAL 235  2.134 
9 Streptomycin  -4.94  -44.669  A:LYS 241 (NH…O)  2.142 
10 Ethambutol  -4.40  -31.959  (OH…O)A:GLY 237 
 (NH…O)A:VAL 235 
3.217 
3.152 
 
Table 2: XP Docking of bioactive compounds from W somnifera with PknG of M. tuberculosis  
S. No  Compounds  Glide Score  Glide Energy  H Bond Interaction  Bond Distance 
(DH…A) Å 
 AX20017  -5.63  -40.423  A:VAL  235  (NH…O) 
(NH…0) A:GLU 233 
3.381 
3.327 
1  Withanolide D  -7.63  -42.901  A:GLN 238 (NH…O) 
A:VAL 235 (NH…O) 
A:SER 239 (OH…O) 
2.779 
3.068 
3.109 
2 Withanolide  A  -4.51  -40.724  A:GLN 238 (NH…O)  3.005 
3  Withanolide E  -7.86  -48.905  A:VAL 235 (NH…O) 
(OH…O) A:GLY 237 
3.094 
2.739 
4  Withanolide F  -7.69  -47.077  A:SER 293 (NH…O) 
A:VAL 235 (NH…O) 
3.375 
2.739 
5 4β-Hydroxywithanolide E  -6.46  -48.767  A:HIS 159 (NH…O) 
(OH…O) A:GLY 237 
2.980 
2.828 
6  Withaferin A  -6.84  -36.108  (OH…O) A:ILE 292 
A:VAL 235 (NH…O) 
2.849 
2.935 
7 Diacetate  2-phenylcarbonate 
withaferin A 
-4.75 -41.948 -  - 
8  2,3 dihydro withaferin A  -4.58  -34.799  A:SER 239 (OH…O) 
(OH…O) A:HIS 159 
A:LYS 241 (NH…O) 
2.856 
2.769 
2.985 
9  2,7 deoxy 2,3 dihydro withaferin A  -4.58  -34.799  A:SER 239 (OH…O) 
(OH…H) A:HIS 159 
A:LYS 241 (NH…O) 
2.856 
2.769 
2.985 
10 Deoxytetrahydroacetate  withaferin  A  -5.73  -41.078  A:GLN 238 (NH…O) 
(OH…O) A:GLY 237 
2.923 
2.979 
 
Table 3: ADME results for the Withanolide compounds 
S. No  Compounds  Molecular 
Weight 
(130.0 to 725.0) 
Donor 
HB 
(0.0 to 6.0) 
Accept 
HB 
(2.0 to 20.0) 
QP LOG 
O/W 
(-2 to 6.5) 
% Human Oral 
Absorption (>80% is 
high & <25% is poor) 
Rule of Five 
 
  Ligand  268.37  2.000 4.500 0.946  77.723  0 
1  Withanolide  D  454.61  1.000 8.700 3.481  100.00  0 
2  Withanolide  A  470.61  2.000 9.450 3.067  91.634  0 
3  Withanolide  E  486.60  3.000 9.250 3.153  95.431  0 
4  Withanolide  F  488.62  4.000 8.950 2.784  81.153  0 
5  Withaferin    500.67  0.000 9.000 3.936  88.150  1 
 